Key Highlights

● Schrodinger, Absci and Recursion all rallied together.

● No company news explained the group's moves.

● The rally spread to genomics and gene-editing names.

● The Russell 2000 small-cap index also rose.

A group of stocks tied to artificial intelligence in drug discovery and genomics rallied in unison, without any company announcements to explain the moves. Schrodinger led the charge, soaring through the session, while Absci and Recursion Pharmaceuticals also jumped, with one market report noting no company news explained the moves in any of the three.

Schrodinger, which sells physics-based computational software for drug design and also develops its own drug candidates, finished sharply higher, while Absci's only release that morning was a notice about attending investor conferences.

Why Group Moves Happen

Recursion, which pairs automated lab experiments with machine learning to find drug candidates, also climbed, and the group rally spread further, with Twist Bioscience, Tempus AI and 10x Genomics all rising, again without company-specific news.

When a basket of thematically linked stocks moves together without news, it often reflects sector flows rather than fundamentals, with traders and funds that track a theme buying or selling the group at once, and modest shifts in demand producing large price swings in relatively small, actively traded companies.

A Busy Day for Biotech Overall

The rally came on an eventful day for the broader biotech sector, with Genmab soaring after a Phase 3 trial of its head and neck cancer treatment met both primary endpoints, and Beam Therapeutics climbing sharply on new clinical data.

There were also steep losses, with Bicara Therapeutics plunging on no company news, a reminder that moves without a clear catalyst can run in either direction.